Breadcrumb

[A13-14] Addendum to Commission A12-16 Saxagliptin/metformin

Overview

Overview

Commission: Commission awarded on 2013-03-27 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Addendum to Commission A12-16 (Saxagliptin/metformin)  [PDF, 443 kB]Further documents
Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Contact address:to the contact form
Linked projects: [A12-16] Saxagliptin/metformin (drug combination) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2013-05-02 Addendum to Commission A12-16 (Saxagliptin/metformin) 443 kBPDFdownload file


At a glance

Accompanying information

Federal Joint Committee (G-BA)

2013-05-02 A G-BA decision was published.

G-BA documents on this decision

Press releases

2013-05-02 IQWiG assessed information subsequently provided by the manufacturers on two dossiers



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close